Suppr超能文献

通过脂质化或与渗透促进剂共同给药实现肝素的胃肠道吸收。

Gastrointestinal absorption of heparin by lipidization or coadministration with penetration enhancers.

作者信息

Ross Benjamin P, Toth Istvan

机构信息

School of Molecular and Microbial Sciences, The University of Queensland, Brisbane, Queensland 4072 Australia.

出版信息

Curr Drug Deliv. 2005 Jul;2(3):277-87. doi: 10.2174/1567201054367968.

Abstract

A review with 93 references. Heparins are high molecular weight, hydrophilic polyanions, which are unstable under acidic conditions; and therefore they exhibit poor oral bioavailability. Consequently they must be administered via the parenteral route which is expensive, inconvenient, and limits use by outpatients. The development of an oral form of heparin is warranted. This review examined the literature, mostly published between January 2000 and January 2005, pertaining to the gastrointestinal absorption of heparin by lipidization or coadministration with penetration enhancers. A lipidization strategy that was examined involved conjugation of low molecular weight heparin with deoxycholic acid. The majority of studies examined the ability of different formulations, typically utilizing penetration enhancers, to improve heparin bioavailability. The penetration enhancers used included fatty acids, Labrasol, Gelucire 44/14, polycationic lipophilic-core dendrons, saponins, mono-N-carboxymethyl chitosan, Carbopol 934P, a combination of thiolated polycarbophil and glutathione, polymeric nanoparticles, polymeric microparticles, sodium N-[8-(2-hydroxybenzoyl) amino]caprylate (SNAC), and sodium N-[10-(2-hydroxybenzoyl)amino]decanoate (SNAD). The variety of models used and doses of heparin/penetration enhancers applied, however, made it difficult to compare the results between studies. Nevertheless, all of the reviewed drug delivery systems showed therapeutic value and confirmation of the promising results obtained from animal studies, by progression to clinical trials, is necessary. Overall, progress has been made in the quest for an oral heparin formulation.

摘要

一篇有93篇参考文献的综述。肝素是高分子量的亲水性聚阴离子,在酸性条件下不稳定;因此它们的口服生物利用度较差。因此,它们必须通过肠胃外途径给药,这既昂贵又不方便,还限制了门诊患者的使用。开发口服形式的肝素是有必要的。这篇综述研究了主要在2000年1月至2005年1月期间发表的有关通过脂质化或与渗透促进剂共同给药来实现肝素胃肠道吸收的文献。所研究的一种脂质化策略涉及低分子量肝素与脱氧胆酸的共轭。大多数研究考察了不同制剂(通常使用渗透促进剂)提高肝素生物利用度的能力。所使用的渗透促进剂包括脂肪酸、Labrasol、Gelucire 44/14、聚阳离子亲脂性核心树枝状分子、皂苷、单-N-羧甲基壳聚糖、卡波姆934P、硫醇化聚卡波非与谷胱甘肽的组合、聚合物纳米颗粒、聚合物微粒、N-[8-(2-羟基苯甲酰基)氨基]辛酸钠(SNAC)和N-[10-(2-羟基苯甲酰基)氨基]癸酸钠(SNAD)。然而,所使用的模型种类以及肝素/渗透促进剂的给药剂量各不相同,使得各研究之间难以比较结果。尽管如此,所有综述的药物递送系统都显示出治疗价值,有必要通过推进到临床试验来证实从动物研究中获得的有前景的结果。总体而言,在寻求口服肝素制剂方面已经取得了进展。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验